Literature DB >> 9506560

Complex I defect in muscle from patients with Huntington's disease.

J Arenas1, Y Campos, R Ribacoba, M A Martín, J C Rubio, P Ablanedo, A Cabello.   

Abstract

We found a variable defect of complex I of the mitochondrial respiratory chain, ranging in severity from 25% to 63% of control values, in muscle of patients with Huntington's disease (HD). The most severe defect was observed in the patient with the greatest expansion of CAG triplets. Muscle morphology showed myopathic changes such as moth-eaten fibers, angulated fibers, increased subsarcolemmal oxidative activities, or an increased number of enlarged mitochondria with abnormal cristae. Multiple mitochondrial DNA deletions were found by polymerase chain reaction (PCR) analysis in muscle of the patient with the most severe defect of complex I. Our data further support the involvement of energetic defects and oxidative damage in muscle of patients with HD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506560     DOI: 10.1002/ana.410430321

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

1.  Ginkgo biloba extracts EGb 761 and bilobalide increase NADH dehydrogenase mRNA level and mitochondrial respiratory control ratio in PC12 cells.

Authors:  Elisabetta A Tendi; Francesca Bosetti; S Fenella Dasgupta; Anna Maria Giuffrida Stella; Katy Drieu; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

Review 2.  Mitochondrial complex I: structure, function and pathology.

Authors:  Rolf J R J Janssen; Leo G Nijtmans; Lambert P van den Heuvel; Jan A M Smeitink
Journal:  J Inherit Metab Dis       Date:  2006-07-11       Impact factor: 4.982

3.  Huntington's disease and mitochondrial DNA deletions: event or regular mechanism for mutant huntingtin protein and CAG repeats expansion?!

Authors:  Mohammad Mehdi Banoei; Massoud Houshmand; Mehdi Shafa Shariat Panahi; Parvin Shariati; Maryam Rostami; Masoumeh Dehghan Manshadi; Tayebeh Majidizadeh
Journal:  Cell Mol Neurobiol       Date:  2007-10-20       Impact factor: 5.046

Review 4.  The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease.

Authors:  Aris A Polyzos; Cynthia T McMurray
Journal:  Mech Ageing Dev       Date:  2016-09-12       Impact factor: 5.432

Review 5.  The neurodegenerative mitochondriopathies.

Authors:  Russell H Swerdlow
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 6.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 7.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 8.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 9.  Neuronal Ca(2+) dyshomeostasis in Huntington disease.

Authors:  Marta Giacomello; Juan C Oliveros; Jose R Naranjo; Ernesto Carafoli
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

10.  Investigation of tRNA(Leu/Lys) and ATPase 6 genes mutations in Huntington's disease.

Authors:  Sadaf Kasraie; Massoud Houshmand; Mohammad Mehdi Banoei; Solmaz Etemad Ahari; Mehdi Shafa Shariat Panahi; Parvin Shariati; Mohammad Bahar; Mostafa Moin
Journal:  Cell Mol Neurobiol       Date:  2008-04-02       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.